Short answer
OmniAb, Inc. (OABI) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (up 78.3% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $4M
- +78.3% YoY · −70.2% QoQ
- Net income
- −$16M
- +4.8% YoY · −168.4% QoQ
- Operating margin
- -409.9%
- EPS (diluted)
- −$0.12
- +14.3% YoY · −140.0% QoQ
Source: XBRL data from the OmniAb, Inc. (OABI) Q3 2026 10-Q on SEC EDGAR. USD.
OmniAb, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $3.993M vs $2.239M, up $1.754M YoY
- Service revenue $2.835M vs $1.188M, strongest growth from antibody and ion channel programs
- Q3 net loss $15.728M vs $16.525M, effective tax rate 0.8% vs 6.6%
- Cash, equivalents and short-term investments $64.2M, sufficient through at least next 12 months
- Nine-month operating cash flow $8.340M vs $(30.781)M, headwinds from lower platform demand and potential tariffs or trade policies
Risk Factors
- No material changes to 2025 Annual Report risk factors
- Carried-forward risk: unknown or currently immaterial factors could materially harm operating results
- Carried-forward risk: general economic conditions could adversely affect cash flows
- Carried-forward risk: existing risks could materially weaken financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OmniAb, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.